دورية أكاديمية
The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study
| العنوان: | The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study |
|---|---|
| المؤلفون: | Ucar, Mehmet Ali, Kaynar, Leylagul, Mehtap, Ozgur, Uysal, Ayse, Sahin, Fahri, Salim, Ozan, Sungur, Mehmet Ali, Tombak, Anil, Akdeniz, Aydan, Tiftik, Eyup Naci, Sahin, Deniz Goren, Akay, Olga Meltem, Yildirim, Murat, Nevruz, Oral, Kis, Cem, Gurkan, Emel, Solmaz, Serife Medeni, Ozcan, Mehmet Ali, Yildirim, Rahsan, Berber, Ilhami, Erkurt, Mehmet Ali, Tuglular, Tulin Firatli, Tarkun, Pinar, Yavasoglu, Irfan, Dogu, Mehmet Hilmi, Sari, Ismail, Merter, Mustafa, Ozcan, Muhit, Yildizhan, Esra |
| بيانات النشر: | Galenos Yayincilik |
| سنة النشر: | 2016 |
| المجموعة: | Ege University Institutional Repository |
| مصطلحات موضوعية: | Acute myeloid leukemia, Elderly, Bone marrow blasts, Prognostic factors, Overall survival, Azacitidine |
| الوصف: | PubMed ID: 27095141 ; WOS: 000392282500002 ; Objective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective multicenter study, 130 patients of >= 60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included. Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment. Median overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of 2, increasing number of AZA cycles (>= 5 courses), and any HI predicted better OS. Age, AML type, and BM blast percentage had no impact. Conclusion: We conclude that AZA is effective and well tolerated in elderly comorbid AML patients, irrespective of BM blast count, and HI should be considered a sufficient response to continue treatment with AZA. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1308-5263 1300-7777 |
| العلاقة: | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Turkish Journal of Hematology; https://hdl.handle.net/11454/53240Test; https://doi.org/10.4274/tjh.2015.0203Test; 33; 273; 280 |
| DOI: | 10.4274/tjh.2015.0203 |
| الإتاحة: | https://doi.org/10.4274/tjh.2015.0203Test https://hdl.handle.net/11454/53240Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.5A14806D |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 13085263 13007777 |
|---|---|
| DOI: | 10.4274/tjh.2015.0203 |